<DOC>
	<DOCNO>NCT02515695</DOCNO>
	<brief_summary>Phase I study aim : - assess absolute bioavailability , pharmacokinetic profile , dose proportionality interferon beta-1a ( HSA-free solution pre-filled syrinx ) i.v . s.c. administration well pharmacodynamic profile create link available surrogate marker investigate formulation use clinically , lyophilisate HSA ( HSA+ ) solution without HSA ( HSA- ) ; - gathering information safety tolerability interferon beta-1a dose range , include local systemic tolerance , body temperature , vital sign , battery exploratory sickness behavior test .</brief_summary>
	<brief_title>Phase I BP Interferon ( IFN ) Beta-001</brief_title>
	<detailed_description />
	<mesh_term>Multiple Sclerosis</mesh_term>
	<mesh_term>Multiple Sclerosis , Relapsing-Remitting</mesh_term>
	<mesh_term>Interferons</mesh_term>
	<mesh_term>Interferon-beta</mesh_term>
	<mesh_term>Interferon beta-1a</mesh_term>
	<criteria>Healthy male female subject age 18 45 year Weight range 55 95 kg male , 45 80 kg female , provide body mass index ( BMI ) 18 29 kg/m2 Absence significant finding medical history physical examination Absence significant laboratory abnormality judge investigator . 12lead ECG without significant abnormality Negative urine drug screen History major renal , hepatic , immunological , haematological , gastrointestinal , genitourinary , neurological , rheumatological disorder Active disease type , even mild , include inflammatory disorder infection . Pregnant lactate woman woman contemplate become pregnant study . Female subject childbearing potential practice efficient contraception study . A pregnancy test blood perform screening period βhuman chorionic gonadotropin female childbearing potential . If pregnancy test positive , subject immediately exclude study follow delivery History severe allergy asthma time . History cardiovascular dysfunction Hypertension Sick sinus syndrome know long QT syndrome Presence QTc ￼ &gt; 440 msec pronounce sinus bradycardia ( &lt; 40 bpm/min ) , even elicit sport Dark skin prevent local tolerance assessment abnormal cutaneous reaction e.g . urticaria papular dermographism Intense sport activity . Any clinically significant laboratory value screen within normal range single repeat Positive hepatitis B &amp; C antigen screen Positive HIV antibody screen screen perform Any recent acute illness sequela thereof could expose subject high risk might confound result study Treatment previous three month drug know welldefined potential toxicity major organ History hypersensitivity drug consider serious History alcohol drug abuse Positive qualitative urine drug test screening Use medication 2 week prior study throughout study , include aspirin overthecounter preparation . Blood ( 500 mL ) donation hemorrhage previous three month Participation clinical trial previous 3 month Smoking Consumption large quantity coffee , tea equivalent Present consumption large quantity alcohol wine equivalent Psychological status could impact subject 's ability give inform consent behavioral test Any feature subject 's medical history present condition , investigator 's opinion , could confound result study , complicate interpretation , represent potential risk subject</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>45 Years</maximum_age>
	<verification_date>August 2015</verification_date>
</DOC>